[1]沈惠群,沈松菲.5-Aza-CdR对胃癌中SOX17基因表达的影响[J].福建医药杂志,2024,46(01):24-29.[doi:10.20148/j.fmj.2024.01.007]
点击复制

5-Aza-CdR对胃癌中SOX17基因表达的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年01期
页码:
24-29
栏目:
临床研究
出版日期:
2024-02-15

文章信息/Info

文章编号:
1002-2600（2024）01-0024-06
作者:
沈惠群1; 沈松菲2
1 福建医科大学附属漳州市医院肿瘤内科，漳州363000；2 福建医科大学附属协和医院肿瘤内科，福州350001
关键词:
胃癌; SOX17基因; 甲基化
分类号:
R735.2
DOI:
10.20148/j.fmj.2024.01.007
文献标志码:
A
摘要:
目的检测胃癌中SOX17的表达情况，探讨5-Aza-CdR对胃癌细胞SOX17表达的影响。方法采用免疫组织化学染色（immunohistochmeistry,IHC）法检测胃癌组织及癌旁组织中SOX17蛋白的表达情况，分析其表达与患者临床病理参数的关系。实时定量聚合酶链式反应（real-time polymerase chain reaction，Real-time PCR）和蛋白质印迹（Western blot）法检测胃癌细胞株MGC-803、MKN-45、AGS及正常胃黏膜细胞株GES-1中SOX17基因 mRNA和蛋白的表达情况。甲基化特异性PCR（methylation specific PCR,MSP）法检测胃癌细胞系SOX17基因启动子区甲基化情况。CCK-8法和流式细胞仪分别检测5-Aza-CdR对AGS细胞增殖和细胞周期的影响。结果与癌旁组织相比，胃癌组织SOX17蛋白阳性表达率明显降低（癌旁组织80.48% vs.胃癌组织19.51%，P<0.001），与胃癌患者性别、年龄、临床分期、分化程度、是否伴脉管癌栓无关。SOX17基因mRNA和蛋白在各胃癌细胞系表达明显降低（P<0.05），且在AGS细胞中表达最低。SOX17基因启动子区在AGS和MKN45细胞中均完全甲基化，MGC-803细胞部分甲基化，GES-1细胞完全非甲基化。去甲基化药物5-Aza-CdR可下调甲基转移酶的表达，逆转SOX17基因甲基化，使其mRNA和蛋白表达上调。5-Aza-CdR还可抑制AGS细胞的增殖并使细胞阻滞于G0/G1期。结论5-Aza-CdR可逆转胃癌细胞SOX17基因甲基化，上调其mRNA和蛋白表达，从而抑制胃癌的发生发展。

参考文献/References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] LIU Y,ASAKURA M,INOUE H,et al.Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells[J].Proc Natl Acad Sci U S A,2007,104(10):3859-3864.
[4] YE Y W,WU J H,WANG C M,et al.Sox17 regulates proliferation and cell cycle during gastric cancer progression[J].Cancer Lett,2011,307(2):124-131.
[5] YIN D,JIA Y,YU Y,et al.SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer[J].Discov Med,2012,14(74):33-40.
[6] HOPMAN A,MOSHI J M,HOOGDUIN K J,et al.SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma[J].Histopathology,2020,76(3):383-393.
[7] JIA Y,YANG Y,ZHAN Q,et al.Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer[J].J Mol Diagn,2012,14(6):577-585.
[8] 郭艳丽,潘盼,郭炜,等.Sox17基因甲基化状态与贲门腺癌发生发展关系研究[J].中国肿瘤临床,2012,39(14):965-969.
[9] 杨恒颖,单治理,孙明浩,等.高龄胃癌患者手术治疗的短期疗效及预后影响因素[J].中国老年学杂志,2019,39(10):2350-2354.
[10] LING Z Q,LV P,LU X X,et al.Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer[J].PLoS One,2013,8(6):e67195.
[11] LING Z Q,GE M H,LU X X,et al.Ndrg2 promoter hypermethylation triggered by helicobacter pylori infection correlates with poor patients survival in human gastric carcinoma[J].Oncotarget,2015,6(10):8210-8225.
[12] DU Y C,OSHIMA H,OGUMA K,et al.Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis[J].Gastroenterology,2009,137(4):1346-1357.
[13] CLARKE R L,YZAGUIRRE A D,YASHIRO-OHTANI Y,et al.The expression of Sox17 identifies and regulates haemogenic endothelium[J].Nat Cell Biol,2013,15(5):502-510.
[14] ZHOU W,WANG K,WANG J,et al.SOX17 inhibits tumor metastasis via Wnt signaling in endometrial cancer[J].Onco Targets Ther,2019,12:8275-8286.
[15] YIN D,JIA Y,YU Y,et al.SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer[J].Discov Med,2012,14(74):33-40.
[16] CHEN H L,CHEW L J,PACKER R J,et al.Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation[J].Cancer Lett,2013,335(2):361-371.
[17] FU D,REN C,TAN H,et al.Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer[J].Medicine(Baltimore),2015,94(11):e637.
[18] LI J Y,HAN C,ZHENG L L,et al.Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma[J].Chin Med J(Engl),2012,125(19):3526-3531.
[19] CHEN Y C,HUANG R L,HUANG Y K,et al.Methylomics analysis identifies epigenetically silenced genes and implies an activation of beta-catenin signaling in cervical cancer[J].Int J Cancer,2014,135(1):117-127.
[20] YE Y W,WU J H,WANG C M,et al. Sox17 regulates proliferation and cell cycle during gastric cancer progression[J].Cancer Lett,2011,307(2)：124-131.
[21] FUKAMACHI H,SHIMADA S,ITO K,et al.CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation[J].Cancer Sci,2011,102(7)：1313-1321.
[22] 郭艳丽,郭炜,张国强,等.胃癌组织中Sox7、Sox17基因甲基化及临床意义[J].中国肿瘤,2015,24(7):613-617.
[23] BALGKOURANIDOU I,KARAYIANNAKIS A,MATTHAIOS D,et al.Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer.Association with prognostic variables and survival[J].Clin Chem Lab Med,2013,51(7):1505-1510.
[24] BRECCIA M,SALAROLI A,LOGLISCI G,et al.5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment[J].Leuk Res,2011,35(10):1409-1411.

相似文献/References:

[1]杨蔡江.胃癌癌组织中p27与cyclinD1的表达及临床意义[J].福建医药杂志,2017,39(5):50.
[2]陈国平 陈剑明.多项肿瘤标记物在胃癌诊断中的筛选及应用价值[J].福建医药杂志,2019,41(02):4.
　CHEN Guoping,CHEN Jianming..Value of screening and application of multiple combined tumor markers in the diagnosis of gastric cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):4.
[3]赵 珅 范南峰 李 惠 刘 捷 俞嘉青 林榕波.阿帕替尼联合紫杉醇化疗方案治疗紫杉醇耐药的晚期胃癌的临床研究[J].福建医药杂志,2020,42(01):16.
　ZHAO Shen,FAN Nanfeng,LI Hui,et al.Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):16.
[4]吕美玲,赖丽萍,吕冬梅,等.干扰MS4A8对苦参碱抑制胃癌细胞生长的影响[J].福建医药杂志,2023,45(05):98.

备注/Memo

备注/Memo:
基金项目：福建医科大学启航基金（2022QH1276）
通信作者：沈松菲，Email:shensongfei@163.com
更新日期/Last Update: 2024-02-15